News
With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback